DrugDashboards

Market view

ocrelizumab and hyaluronidase

2 marketed package NDCs · 1 active manufacturer

The short version

Only one company currently supplies this market — there is no backup if it stumbles.

What changed in the last 90 days

Every detected change for ocrelizumab and hyaluronidase, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.

  • Ocrevus ZunovoSep 2, 2026
    Mfr exited
    Genentech, Inc. · ocrelizumab and hyaluronidase
  • Ocrevus ZunovoAug 26, 2026
    Mfr entered
    Genentech, Inc. · ocrelizumab and hyaluronidase
  • Ocrevus ZunovoJul 29, 2026
    Mfr exited
    Genentech, Inc. · ocrelizumab and hyaluronidase
  • Ocrevus ZunovoJul 22, 2026
    Mfr entered
    Genentech, Inc. · ocrelizumab and hyaluronidase

Same drug class

Other molecules FDA puts in Endoglycosidase, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

Common questions

Is Ocrelizumab and hyaluronidase in shortage right now?
No. FDA does not currently list Ocrelizumab and hyaluronidase in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
Who makes Ocrelizumab and hyaluronidase?
1 company has marketed Ocrelizumab and hyaluronidase in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.

All marketed products

Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.